Form 4: Entrada Therapeutics Director Peter S. Kim Acquires 16,000 Stock Options
SEC Form 4 Filing
Director Peter S. Kim acquired 16,000 stock options in Entrada Therapeutics, Inc. on June 13, 2024.
Summary
- On June 13, 2024, Peter S. Kim, a director of Entrada Therapeutics, Inc., acquired 16,000 stock options.
- The exercise price of these options is $16.45.
- The options vest on the earlier of the one-year anniversary of the grant date or the Issuer's next annual meeting of stockholders.
- The options expire on June 13, 2034.
- Following the transaction, Kim directly owns 16,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option grants, so the sentiment is neutral.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. It is common for directors and officers to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders, as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of earliest transaction: Peter S. Kim acquired 16,000 stock options at $16.45. |
| 06/13/2024 | Stock options granted. |
| 06/13/2034 | Expiration date of the stock options. |
| 06/14/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.